Zhangzhou Pientzehuang Pharmaceutical Co Ltd: Strategic Leadership Changes Amid Financial Adjustments

In a significant move to bolster its governance structure, Zhangzhou Pientzehuang Pharmaceutical Co Ltd, a prominent player in the traditional Chinese medicine sector, has announced a series of strategic leadership changes. The company, listed on the Shanghai Stock Exchange, has seen its market value decline from a peak of 485.95 CNH per share in 2021 to 201.94 CNH as of August 13, 2025, reflecting a substantial market value erosion of 1700 billion CNH.

On August 14, 2025, the company disclosed two key announcements regarding personnel adjustments. In an effort to enhance its governance framework, Zhangzhou Pientzehuang has appointed Mr. He Wei as Deputy General Manager and Mr. Wei Tengyun as Chief Engineer. Mr. He Wei, with a decade of experience in various departments of the Zhangzhou municipal government, including comprehensive, information, and industrial transportation sectors, joined the company in August 2025 as a party committee member and has now been appointed as Deputy General Manager. Mr. Wei Tengyun, with a solid technical background from his long-term frontline production roles, currently serves as the company’s worker supervisor and first workshop director.

These appointments were recommended by the controlling shareholder and approved by the board’s nomination committee, which found both candidates to meet the qualifications for executive roles without any regulatory violations. Concurrently, the company has restructured its board audit committee, replacing the existing members with Zhang Lei (Chairman), Du Shouying, and Chen Lei to ensure effective committee operations.

In addition to these changes, the company has seen other significant personnel shifts. Earlier in the year, board member and company secretary Chen Honghui, along with Deputy General Manager Hong Fei, resigned from their positions, with the company subsequently appointing Shi Yixiong as Deputy General Manager. Mr. Shi Yixiong, whose career began in local government, has held various party and government positions before transitioning to high-level roles in major state-owned enterprises in Zhangzhou, joining Pientzehuang in early 2025 as a party committee member and Deputy General Manager.

Financially, the company has experienced notable activity in its capital markets. On August 14, 2025, Pientzehuang received margin buying of 83.44 million CNH, accounting for 19.21% of the day’s inflow, with the current margin balance standing at 174 million CNH, representing 1.43% of the circulating market value. This margin balance exceeds the historical 60% percentile level. In terms of margin selling, the company saw a repayment of 1300 shares and a sale of 1400 shares, with the selling amount calculated at 282.7 thousand CNH, a mere 0.08% of the day’s outflow, and a margin balance of 11.28 million shares, below the historical 50% percentile level.

These strategic leadership changes and financial maneuvers come at a critical time for Zhangzhou Pientzehuang as it navigates the challenges of a competitive pharmaceutical market and seeks to reinforce its position in the traditional Chinese medicine industry. With a focus on strengthening governance and financial stability, the company aims to chart a course towards sustainable growth and market recovery.